Skip to main content
Top
Literature
3.
go back to reference M. Vaduganathan, S.J. Greene, A.P. Ambrosy, R.J. Mentz, H.P. Subacius, O. Chioncel, A.P. Maggioni, K. Swedberg, F. Zannad, M.A. Konstam, M. Senni, M.M. Givertz, J. Butler, M. Gheorghiade, EVEREST trial investigators. Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). Am. J. Cardiol. 114(11), 1713–1721 (2014). https://​doi.​org/​10.​1016/​j.​amjcard.​2014.​09.​008 CrossRefPubMed M. Vaduganathan, S.J. Greene, A.P. Ambrosy, R.J. Mentz, H.P. Subacius, O. Chioncel, A.P. Maggioni, K. Swedberg, F. Zannad, M.A. Konstam, M. Senni, M.M. Givertz, J. Butler, M. Gheorghiade, EVEREST trial investigators. Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). Am. J. Cardiol. 114(11), 1713–1721 (2014). https://​doi.​org/​10.​1016/​j.​amjcard.​2014.​09.​008 CrossRefPubMed
Metadata
Title
Uric acid levels with tolvaptan treatment for syndrome of inappropriate antidiuretic hormone secretion
Author
Takahiko Nagamine
Publication date
20-11-2023
Publisher
Springer US
Published in
Endocrine
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-023-03612-3